- Home
- FOLD vs RYTM Comparison
FOLD vs RYTM Comparison
Compare FOLD & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOLD
- RYTM
- Stock Information
- Founded
- FOLD 2002
- RYTM 2008
- Country
- FOLD United States
- RYTM United States
- Employees
- FOLD N/A
- RYTM N/A
- Industry
- FOLD Biotechnology: Pharmaceutical Preparations
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- FOLD Health Care
- RYTM Health Care
- Exchange
- FOLD Nasdaq
- RYTM Nasdaq
- Market Cap
- FOLD 2.9B
- RYTM 3.2B
- IPO Year
- FOLD 2007
- RYTM 2017
- Fundamental
- Price
- FOLD $8.43
- RYTM $54.80
- Analyst Decision
- FOLD Strong Buy
- RYTM Strong Buy
- Analyst Count
- FOLD 9
- RYTM 12
- Target Price
- FOLD $17.00
- RYTM $68.58
- AVG Volume (30 Days)
- FOLD 2.6M
- RYTM 544.5K
- Earning Date
- FOLD 05-08-2025
- RYTM 05-06-2025
- Dividend Yield
- FOLD N/A
- RYTM N/A
- EPS Growth
- FOLD N/A
- RYTM N/A
- EPS
- FOLD N/A
- RYTM N/A
- Revenue
- FOLD $528,294,999.00
- RYTM $130,126,000.00
- Revenue This Year
- FOLD $21.91
- RYTM $47.06
- Revenue Next Year
- FOLD $22.22
- RYTM $68.10
- P/E Ratio
- FOLD N/A
- RYTM N/A
- Revenue Growth
- FOLD 32.29
- RYTM 68.06
- 52 Week Low
- FOLD $8.36
- RYTM $35.17
- 52 Week High
- FOLD $12.65
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- FOLD 35.37
- RYTM 53.63
- Support Level
- FOLD $8.40
- RYTM $52.54
- Resistance Level
- FOLD $9.26
- RYTM $55.87
- Average True Range (ATR)
- FOLD 0.25
- RYTM 2.15
- MACD
- FOLD -0.04
- RYTM 0.47
- Stochastic Oscillator
- FOLD 7.78
- RYTM 86.57
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.